SPONSOR
RemeGen Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 1, Phase 2, Phase 3
RemeGen Co., Ltd. is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Breast Cancer, Solid Tumors, Urothelial Carcinoma, HER2-expressing.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — RemeGen Co., Ltd.
How many clinical trials has RemeGen Co., Ltd. sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by RemeGen Co., Ltd., of which 5 are actively recruiting participants. These trials cover conditions including Breast Cancer, Solid Tumors, Urothelial Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does RemeGen Co., Ltd. research focus on?
RemeGen Co., Ltd. clinical trials span Breast Cancer, Solid Tumors, Urothelial Carcinoma, HER2-expressing, Gastric Carcinoma. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a RemeGen Co., Ltd. clinical trial?
To participate in a RemeGen Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all RemeGen Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by RemeGen Co., Ltd.
NCT06642545 Phase 2
Recruiting
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Breast Cancer
NCT07105215 Phase 1, Phase 2
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Solid Tumors
NCT05302284 Phase 3
Recruiting
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Urothelial Carcinoma
NCT04400695 Phase 3
Recruiting
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Breast Cancer
NCT07315750 Phase 3
Recruiting
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Gastric Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology